New Methods for Producing Praziquantel as a Single Enantiomer
Author Information
Author(s): Michael Woelfle, Jean-Paul Seerden, Jesse de Gooijer, Kees Pouwer, Piero Olliaro, Matthew H. Todd
Primary Institution: School of Chemistry, The University of Sydney
Hypothesis
Can enantiopure praziquantel be obtained without a significant increase in price?
Conclusion
Both resolution procedures identified show promise for the large-scale, economically viable production of praziquantel as a single enantiomer for a low price.
Supporting Evidence
- Praziquantel is the main drug used to treat schistosomiasis.
- The inactive enantiomer of praziquantel causes side effects and a bitter taste.
- Open collaboration led to the discovery of new methods for producing praziquantel.
- Both methods can produce enantiopure praziquantel economically.
- Smaller quantities of the drug can be produced for research purposes.
Takeaway
Researchers found two ways to make praziquantel, a medicine for schistosomiasis, in a purer form that is cheaper and easier to use.
Methodology
Two resolution approaches were identified: one through hydrolysis of praziquantel and another using a different intermediate resolved with tartaric acid.
Limitations
The methods may not be suitable for all laboratories due to the need for specific conditions and materials.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website